Harrison Seth Loring reported grant involving 17,786 derivative units of Stoke Therapeutics, Inc. at $0.00 for $0 on Jun 3, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Jun 5, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
17,786Director Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
17,786Direct
Trade date
Jun 3, 2026Grant
Filed
Jun 5, 2026, 4:26 PM ET2-day reporting delay
Accession
0001404955-26-000002Code A · Transaction 98955
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

STOK price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
STOK · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +14%1w ago +4.8%1d ago −4.4%
Returns since7d −0.6%30d +9%90d180d1y

Footnotes in full

F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.